Sherry X. Yang

4.3k total citations · 1 hit paper
54 papers, 3.2k citations indexed

About

Sherry X. Yang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sherry X. Yang has authored 54 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 26 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Sherry X. Yang's work include Epigenetics and DNA Methylation (10 papers), Breast Cancer Treatment Studies (9 papers) and HER2/EGFR in Cancer Research (7 papers). Sherry X. Yang is often cited by papers focused on Epigenetics and DNA Methylation (10 papers), Breast Cancer Treatment Studies (9 papers) and HER2/EGFR in Cancer Research (7 papers). Sherry X. Yang collaborates with scholars based in United States, Malaysia and Japan. Sherry X. Yang's co-authors include Naoko Takebe, Dat Nguyen, Lucio Miele, S. Percy Ivy, Michaël Kahn, Pamela Jo Harris, Woondong Jeong, Hideaki Bando, Eric C. Polley and Sandra M. Swain and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

Sherry X. Yang

50 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

2015 988 citations Naoko Takebe, Lucio Miele et al. Nature Reviews Clinical Oncology profile →

Peers

Sherry X. Yang

ONCOL

PRM

RNMI

Giulio Francia United States

Li‐E Wang United States

Junichi Kurebayashi Japan

Mahmoud Toulany Germany

H. Peter Rodemann Germany

Ewan K.A. Millar Australia

Alberto Bottini Italy

Anne Hansen Ree Norway

Adrian M. Jubb United Kingdom

Mohammed A. Aleskandarany United Kingdom

Giulio Francia United States

Sherry X. Yang

1.5k ×0.8

1.5k ×1.0

ONCOL

849 ×0.9

540 ×1.5

PRM

257 ×0.9

RNMI

Citations per year, relative to Sherry X. Yang Sherry X. Yang (= 1×) peers Giulio Francia

Countries citing papers authored by Sherry X. Yang

Since Specialization

Citations

This map shows the geographic impact of Sherry X. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry X. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry X. Yang more than expected).

Fields of papers citing papers by Sherry X. Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry X. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry X. Yang. The network helps show where Sherry X. Yang may publish in the future.

Co-authorship network of co-authors of Sherry X. Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry X. Yang. A scholar is included among the top collaborators of Sherry X. Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry X. Yang. Sherry X. Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laranjeira, Angelo B. A., Melinda G. Hollingshead, Dat Nguyen, et al.. (2023). DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. Scientific Reports. 13(1). 5964–5964. 39 indexed citations

Verma, Siddharth, Justin Fu, Sherry X. Yang, & Sergey Levine. (2022). CHAI: A CHatbot AI for Task-Oriented Dialogue with Offline Reinforcement Learning. Proceedings of the 2022 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies. 12 indexed citations

Yang, Sherry X., Melinda G. Hollingshead, Larry Rubinstein, et al.. (2021). TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models. Journal of Hematology & Oncology. 14(1). 83–83. 8 indexed citations

Nguyen, Dat, John S. Yu, William C. Reinhold, & Sherry X. Yang. (2020). Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer. JAMA Network Open. 3(7). e207213–e207213. 21 indexed citations

Laranjeira, Angelo B. A. & Sherry X. Yang. (2016). Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic. Expert Opinion on Drug Discovery. 11(11). 1071–1080. 12 indexed citations

Yang, Sherry X., Eric C. Polley, & Stanley Lipkowitz. (2016). New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treatment Reviews. 45. 87–96. 189 indexed citations

Takebe, Naoko, Lucio Miele, Pamela Jo Harris, et al.. (2015). Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nature Reviews Clinical Oncology. 12(8). 445–464. 988 indexed citations breakdown →

Takebe, Naoko, Dat Nguyen, & Sherry X. Yang. (2013). Targeting Notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacology & Therapeutics. 141(2). 140–149. 312 indexed citations

Antony, Smitha, Stephen M. Hewitt, Guojian Jiang, et al.. (2013). Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody. International Journal of Oncology. 42(4). 1229–1238. 39 indexed citations

10.

Chen, Min, Akbar Nawab, Sherry X. Yang, et al.. (2011). DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer. Molecular Cancer Therapeutics. 11(2). 370–382. 47 indexed citations

11.

Nguyen, Diana, Maria Zajac‐Kaye, Larry Rubinstein, et al.. (2011). Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle. 10(23). 4074–4082. 31 indexed citations

12.

Yang, Sherry X., Shivaani Kummar, Seth M. Steinberg, et al.. (2009). Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biology & Therapy. 8(21). 2004–2009. 21 indexed citations

13.

Yang, Sherry X.. (2009). Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Review of Anticancer Therapy. 9(12). 1715–1725. 16 indexed citations

14.

Portera, Chia C., Janice M. Walshe, Douglas R. Rosing, et al.. (2008). Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Clinical Cancer Research. 14(9). 2710–2716. 125 indexed citations

15.

Kummar, Shivaani, Larry Rubinstein, Robert J. Kinders, et al.. (2008). Phase 0 Clinical Trials: Conceptions and Misconceptions. The Cancer Journal. 14(3). 133–137. 68 indexed citations

16.

Ji, Jay, Ravithat Putvatana, Yiping Zhang, et al.. (2007). A validated assay for gamma-H2AX as a pharmacodynamic biomarker of response to DNA damage. Cancer Research. 67. 4027–4027. 1 indexed citations

17.

Tan, Antoinette R., Seth M. Steinberg, Allyson L. Parr, Dao Nguyen, & Sherry X. Yang. (2007). Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Annals of Oncology. 19(1). 185–190. 19 indexed citations

18.

Kinders, Robert J., Ralph E. Parchment, Shivaani Kummar, et al.. (2007). Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. Molecular Interventions. 7(6). 325–334. 54 indexed citations

19.

Kummar, Shivaani, Robert J. Kinders, Larry Rubinstein, et al.. (2007). Compressing drug development timelines in oncology using phase '0' trials. Nature reviews. Cancer. 7(2). 131–139. 145 indexed citations

20.

Denduluri, Neelima, Antoinette R. Tan, Janice M. Walshe, et al.. (2005). A Pilot Study to Evaluate the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor AZD2171 and Chemotherapy in Locally Advanced and Inflammatory Breast Cancer. Clinical Breast Cancer. 6(5). 460–463. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact